| Document Date: 2014-12-23 18:59:08
Open Document File Size: 69,76 KBShare Result on Facebook
City South San Francisco / Tokyo / / Company Amgen / Skeletal Muscle Activator Collaboration Page 3 Astellas Pharma Inc. / Astellas Pharma Inc. / Committed Capital / Cytokinetics Incorporated / Reimbursements For Planned Activities Companies Plan / Tokyo Stock Exchange / / Continent North America / Europe / / Country Japan / United States / Canada / / Currency USD / / Event Business Partnership / FDA Phase / Funding / Conference Call / Product Issues / / Facility Act's Safe Harbor / / IndustryTerm news media / treatment of neuromuscular diseases / chemical energy / pharmaceutical / treatment of serious diseases / biopharmaceutical / pharmaceuticals / manufacturing / biological infrastructure / / MedicalCondition common fatal genetic disorders / muscle fatigue / progressive muscle weakness / neuromuscular diseases / ALS / muscle weakness / severe neuromuscular disease / amyotrophic lateral sclerosis / fatigue / acute and chronic heart failure / muscle contraction / serious diseases / Spinal Muscular Atrophy / disease / Kidney diseases / diseases / Infectious diseases / / MedicalTreatment alternative therapies / / Organization U.S. Food and Drug Administration / Securities and Exchange Commission / / Person Yoshihiko Hatanaka / Robert I. Blum / / / Position global category leader / President and Chief Executive Officer / Private / / Product therapeutic efficacy / SMA / CK-2127107 / the U.S. Food and Drug Administration / ALS / / ProvinceOrState California / / Technology Neuroscience / Transplantation / pharmacokinetics / pharmacodynamics / / URL http /
SocialTag |
CYTOKINETICS AND ASTELLAS ANNOUNCE EXPANSION OF COLLABORATION FOR DEVELOPMENT OF CK[removed]IN SPINAL MUSCULAR ATROPHY AND OTHER NEUROMUSCULAR INDICATIONS Cytokinetics Expects to Receive Over $75 Million in Committed Cap